Description du projet
Un dispositif portable non invasif pour le suivi des biomarqueurs du syndrome métabolique
Le syndrome métabolique se caractérise par une obésité abdominale, une pression artérielle élevée, une altération de la glycémie à jeun, des taux élevés de triglycérides et de faibles taux de HDL. Ce groupe de pathologies augmente le risque de maladies cardiovasculaires, de diabète de type 2 et d'accidents vasculaires cérébraux. Le syndrome métabolique est en hausse en Europe et dans le monde entier, mais il n’est généralement pas diagnostiqué tant que les patients ne présentent pas de symptômes et ou ne consultent un médecin. Le projet MiWear, financé par le CEI, se propose de développer un dispositif portable non invasif pour mesurer des biomarqueurs clés tels que l'acide urique, l'albumine ou les corps cétoniques. L'objectif est de suivre le syndrome métabolique depuis la phase prodromique jusqu’à la phase symptomatique. Les biomarqueurs seront mesurés par spectroscopie dans l'infrarouge moyen du liquide interstitiel de la peau. À terme, MiWear entend réduire le risque de syndrome métabolique.
Objectif
Modern medicine has improved dramatically through a better understanding of what causes a condition or what it is correlated to. However, the healthcare system still follows an episodic (reactive) model, where patients only seek medical advice when there are symptoms, which, for certain medical conditions, has proven critically insufficient. In this context, one of the main burdens for our socioeconomic system in Europe by a single disease is without question the metabolic syndrome (MbS). MbS is prominently visible in the large and ever-growing number of overweight or obese individuals. Yet, its true negative dramatic consequences among others are arteriosclerosis, hereby induced myocardial infarction, and stroke. Several biomarkers such as uric acid, albumin, or ketone bodies correlate with MbS and often indicate different aspects of the metabolic syndrome. The more biomarkers can be measured and quantified with high accuracy, the easier it becomes to make conclusive decisions on the patient’s status. False negatives as well as false positives can be avoided much better with more parameters – if each of them is measured individually and directly without the need for indirect methods where evaluations are easily overfitted.
We provide an alternative approach for the measurement of biomarkers, using a miniatured Mid-Infrared spectrometer, a technology that is only used in laboratories due to its size and cost. The result of the project will be a wearable device to detect biomarkers non-invasively and pain-free in the interstitial fluid in the skin.
For MiWear, we have gathered an impressive consortium combining expert knowledge on biomarkers, optical spectroscopy, laser physics, business management, finances, and the gender dimension of biomarkers. During the project, we will generate opportunities for young researchers, and engage with different stakeholders to ensure maximum outreach of our research and development activities.
Champ scientifique
- natural sciencescomputer and information sciencesinternetinternet of things
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesbasic medicineneurologystroke
- social scienceseconomics and businessbusiness and management
- natural sciencesphysical sciencesopticslaser physics
Mots‑clés
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC - HORIZON EIC GrantsCoordinateur
12489 BERLIN
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.